Ankylosing Spondylitis

Clinical Characteristics of Patients With AS Who Discontinue TNFis Explored

Clinical Characteristics of Patients With AS Who Discontinue TNFis Explored

To compare the characteristics of patients who discontinued TNFis with those who did not, researchers used the Corrona PsA/SpA Registry to identify patients with AS who were on a TNFi and had ≥2 follow-up visits.

Differences in Ankylosing Spondylitis Outcomes Vary by Gender

Clinical improvements during treatment with TNF-α inhibitors was comparable between men and women with ankylosing spondylitis.

Hospitalized Infection Risk Not Linked to DMARD, TNFi Use in Ankylosing Spondylitis

No clear evidence links the risk for hospitalized infection and the use of DMARDs or anti-TNF agents in patients with ankylosing spondylitis.

Risk for Total Knee Arthroplasty Elevated in Ankylosing Spondylitis

The risk for primary total knee arthroplasty is elevated in young and middle-aged adults with ankylosing spondylitis.

Assessment of Simultaneous Occurrence of Ankylosing Spondylitis and Diffuse Idiopathic Skeletal Hyperostosis

Researchers explored the co-occurrence of ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis.

TNFi Effectively Decreases Radiographic Progression in Early Ankylosing Spondylitis

Effective suppression of inflammation with tumor necrosis factor inhibitor therapy decreases radiographic progression in early ankylosing spondylitis.

Rates of Knee, Hip Arthroplasty Increasing Among Patients With Ankylosing Spondylitis

Researchers observed increased rates of both knee and hip arthroplasties in older patients with ankylosing spondylitis.

Lower Cardiorespiratory Fitness Associated With Increased CVD Risk in Ankylosing Spondylitis

Reduced cardiorespiratory fitness may be associated with increased risk for CVD in ankylosing spondylitis.

Risankizumab May Not Be Effective in Treatment of Ankylosing Spondylitis

Treatment with risankizumab was not effective in reducing the signs and symptoms of ankylosing spondylitis at 12 weeks.

Ankylosing Spondylitis Linked to Increased Prevalence of Left Ventricular Hypertrophy

Data strengthen the indication for performing a thorough CVD risk assessment in patients with inflammatory disorders.

Sign Up for Free e-newsletters